Mixed day for RepliCel today. BIG opening volume with a relatively stable price. Then a drop on big volume and a rebound on moderate volume. There was more volume on the downward moves than there was on the upward ones.
I just heard from Heather at Replicel. Here is what she said:
"Good Afternoon Mr. (named removed),
The deadline to file the 2011 Annual Report is April 29th. The Company is on track to file on or before that date.
Kind Regards,
Heather"
My theory is that the trial results will be contained in the Annual report. As most companies do not release or file over the weekend, that could put it back to April 27th. Additionally, from an information sensitivity standpoint, it may make sense to have it released prior to having it included in the auditor-reviewed annual report, as the chance of a leak would be decreased. That is purely a guess on my part, however.
Imagine HOW EMBARRASSING it would be if it turns out to be bullshit?
Probably not so much. Other than guys on Internet hair loss forums, some stock speculators, and those involved in a very specialized area of the medical industry, hardly anyone is paying much attention to Replicel right now.
NBT could just be blowing smoke, but they get their talking points straight from RepliCel. Two of their recent articles use the term "big reveal" and reference a media tour.
Something that's a "big reveal" to stock pumpers/speculators isn't necessarily so to the mainstream news media.
We've all seen how news stories about "cures for baldness" come and go: they hit the news cycle for a day or so, and then they disappear. Without some dramatic visual evidence to show off (like B/A pictures of a NW6 turned NW2), I don't see Replicel's results getting much more play than any of those other stories, no matter how the trials turn out -- no dramatic visual evidence is going to come out of injecting the temples of a handful of test subjects.
NBT could just be blowing smoke, but they get their talking points straight from RepliCel. Two of their recent articles use the term "big reveal" and reference a media tour.
Because it likely isn't going to be a "big reveal"; it's just going to be a determination of whether there's enough potential to merit continuing with more Phase II trials, where plenty of other treatments have crashed and burned.
NBT could just be blowing smoke, but they get their talking points straight from RepliCel. Two of their recent articles use the term "big reveal" and reference a media tour.
If their procedure is gonna work, why pay some penny stock blogs to pump your stock just 2 weeks before the "big reveal"?
Because it likely isn't going to be a "big reveal"; it's just going to be a determination of whether there's enough potential to merit continuing with more Phase II trials, where plenty of other treatments have crashed and burned.
One other catalyst I saw. It looks like there are a bunch of the "penny stock companies" and "momentum" stock investing services that are published reports on Replicel in the last couple of days in addition to NBT. Here are a couple for example:
What is moving the Stock Market Today? Get updates on top gainers, and the current market trends.
If just a few people that are into penny stock investing start buying stock, that can be another explanation for today's activity.
Man, RepliCel paying for all these stock ads is quite unsettling. I could tolerate NBT, although Tobin Smith is a hack, he at least has some credibility. These though seem like the kind of scam stock e-mails that end up in my spam folder. If their procedure is gonna work, why pay some penny stock blogs to pump your stock just 2 weeks before the "big reveal"? If it works, it will be on the front page of Yahoo finance in an article written by an objective journalist and every retail investor in the world will know about it.
One other catalyst I saw. It looks like there are a bunch of the "penny stock companies" and "momentum" stock investing services that are published reports on Replicel in the last couple of days in addition to NBT. Here are a couple for example:
Today's action was interesting and a good follow-up to yesterday. From a technical perspective, they buying action was positive in that often times early morning activity is generally understood to be driven by smaller retail investors while afternoon activity is generally understood to be driven by professionals and larger players.
Still, this is a very small stock and the volume today is still not that significant. Also, volume pick up would be expected as Replicel nears their announcement date.
One can hope that retail investors are getting chickened out and selling in the morning and those in the know are picking up shares in the afternoon as has been the case the last two days. Keep an eye on for the next couple of days.
Leave a comment: